tetano
Editor, Senior Moderator
Antimicrob Agents Chemother
. 2024 Feb 20:e0127323.
doi: 10.1128/aac.01273-23. Online ahead of print. A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness
David Plotnik[SUP] 1 [/SUP], Jennifer E Sager[SUP] 1 [/SUP], Madhukar Aryal[SUP] 1 [/SUP], Marie C Fanget[SUP] 1 [/SUP], Alessia Peter[SUP] 2 [/SUP], Michael A Schmid[SUP] 2 [/SUP], Deborah Cebrik[SUP] 1 [/SUP], Erik Mogalian[SUP] 1 [/SUP], Keith Boundy[SUP] 1 [/SUP], Wendy W Yeh[SUP] 1 [/SUP], Paul Griffin[SUP] 3 [/SUP], Maribel Reyes[SUP] 1 [/SUP]
Affiliations
To evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of VIR-2482 in healthy adult subjects. A phase 1, first-in-human, randomized, double-blind, placebo-controlled dose-escalation study was conducted. One hundred participants were allocated to four cohorts (60 mg, 300 mg, 1,200 mg, and 1,800 mg). In each cohort, participants were randomized in a 4:1 ratio (active
lacebo) to receive either VIR-2482 or volume-matched placebo by gluteal intramuscular injection. Participants remained at the investigative site under observation for 48 h, and adverse events (AEs) were collected for 56 days. PK and immunogenicity were measured up to 52 weeks post-dose. VIR-2482 was well tolerated at all doses studied. The overall incidence of AEs was comparable between VIR-2482 (68.8%) and placebo (85.0%). Nineteen VIR-2482 (23.8%) and six placebo (30.0%) recipients had Grade 1 or 2 AEs that were considered to be related to the study intervention. There were no treatment-related serious AEs. Injection-site reactions (ISRs) were reported in six (7.5%) VIR-2482 recipients, while no such reactions were reported among the placebo recipients. All ISRs were Grade 1, and there was no relationship with the dose. Median VIR-2482 serum elimination half-life ranged from 56.7 to 70.6 days across cohorts. The serum area under the curve and C[SUB]max[/SUB] were dose-proportional. Nasopharyngeal VIR-2482 concentrations were approximately 2%-5% of serum levels and were less than dose-proportional. The incidence of immunogenicity across all cohorts was 1.3%. The safety, tolerability, and pharmacokinetic profile of VIR-2482 at doses up to 1,800 mg supported its further investigation as a long-acting antibody for the prevention of influenza A illness. This study has been registered at ClinicalTrials.gov under identifier NCT04033406.
Keywords: VIR-2482; human immunoglobulin G1; influenza; monoclonal antibodies; prophylaxis
. 2024 Feb 20:e0127323.
doi: 10.1128/aac.01273-23. Online ahead of print. A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness
David Plotnik[SUP] 1 [/SUP], Jennifer E Sager[SUP] 1 [/SUP], Madhukar Aryal[SUP] 1 [/SUP], Marie C Fanget[SUP] 1 [/SUP], Alessia Peter[SUP] 2 [/SUP], Michael A Schmid[SUP] 2 [/SUP], Deborah Cebrik[SUP] 1 [/SUP], Erik Mogalian[SUP] 1 [/SUP], Keith Boundy[SUP] 1 [/SUP], Wendy W Yeh[SUP] 1 [/SUP], Paul Griffin[SUP] 3 [/SUP], Maribel Reyes[SUP] 1 [/SUP]
Affiliations
- PMID: 38376227
- DOI: 10.1128/aac.01273-23
To evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of VIR-2482 in healthy adult subjects. A phase 1, first-in-human, randomized, double-blind, placebo-controlled dose-escalation study was conducted. One hundred participants were allocated to four cohorts (60 mg, 300 mg, 1,200 mg, and 1,800 mg). In each cohort, participants were randomized in a 4:1 ratio (active
lacebo) to receive either VIR-2482 or volume-matched placebo by gluteal intramuscular injection. Participants remained at the investigative site under observation for 48 h, and adverse events (AEs) were collected for 56 days. PK and immunogenicity were measured up to 52 weeks post-dose. VIR-2482 was well tolerated at all doses studied. The overall incidence of AEs was comparable between VIR-2482 (68.8%) and placebo (85.0%). Nineteen VIR-2482 (23.8%) and six placebo (30.0%) recipients had Grade 1 or 2 AEs that were considered to be related to the study intervention. There were no treatment-related serious AEs. Injection-site reactions (ISRs) were reported in six (7.5%) VIR-2482 recipients, while no such reactions were reported among the placebo recipients. All ISRs were Grade 1, and there was no relationship with the dose. Median VIR-2482 serum elimination half-life ranged from 56.7 to 70.6 days across cohorts. The serum area under the curve and C[SUB]max[/SUB] were dose-proportional. Nasopharyngeal VIR-2482 concentrations were approximately 2%-5% of serum levels and were less than dose-proportional. The incidence of immunogenicity across all cohorts was 1.3%. The safety, tolerability, and pharmacokinetic profile of VIR-2482 at doses up to 1,800 mg supported its further investigation as a long-acting antibody for the prevention of influenza A illness. This study has been registered at ClinicalTrials.gov under identifier NCT04033406.Keywords: VIR-2482; human immunoglobulin G1; influenza; monoclonal antibodies; prophylaxis